In summary, this study expands our understanding of glucagon’s role in pNET pathophysiology, emphasizing the significance of metabolic regulation in tumour adaptation and highlighting GCGR as a key candidate for future biomarker development and targeted therapy. Here, GCG is linked to neoplasm.